Global trial finds treatment with amivantamab and lazertinib halts progression for average of 23.7 months

Doctors are hailing “amazing” trial results that show a new drug combination stopped lung cancer advancing for more than 40% longer than the standard treatment.

Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8 million deaths every year. Survival rates in those with advanced forms of the disease, where tumours have spread, are particularly poor.

Patients diagnosed with advanced forms of lung cancer who took the combination of amivantamab and lazertinib were still alive with no progression in their disease after 23.7 months on average, according to data from the global study. Average progression-free survival in patients using the standard drug, osimertinib, was 16.6 months, the trial found.